Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 13/20 | 0.43 |
| ▸ | JAK3 | P52333 | 13/20 | 0.43 |
| ▸ | JAK1 | P23458 | 13/20 | 0.43 |
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805745 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KITJAK2JAK3JAK1 | |
| SCHEMBL3719569 | 0.84 | JAK1 (0.49) | ALDH1A1KITJAK2JAK3JAK1 | |
| SCHEMBL3723654 | 0.81 | KIT (0.46) | ALDH1A1KITJAK2JAK3JAK1 | |
| SCHEMBL3723058 | 0.78 | KIT (0.48) | KITJAK2JAK3JAK1 | |
| SCHEMBL3724527 | 0.76 | RPS6KA3 (0.53) | KITJAK3 | |
| SCHEMBL22613270 | 0.76 | JAK3 (0.60) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL22613274 | 0.76 | JAK3 (0.60) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL2104963 | 0.74 | JAK3 (0.52) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL3727273 | 0.74 | KIT (0.45) | ALDH1A1KITJAK3JAK1 | |
| SCHEMBL3723380 | 0.73 | RPS6KA3 (0.44) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ALDH1A1 2477/4885KIT 1127/4885JAK2 912/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ALDH1A1 2396/4885KIT 1158/4885JAK2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.